ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that ILUVIEN® will be highlighted in four posters to be presented at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in New Orleans, Louisiana from April 23-27, 2023.
Key ILUVIEN Abstracts (presented as posters):
ARVO is among the largest vision research meetings held annually in the field of ophthalmology. Annual meeting educational content is planned by the ARVO program committee, and ARVO does not endorse, promote, approve or recommend the use of any products, devices or services.
About PALADIN
The PALADIN study was a phase 4, open-label, prospective, observational study conducted over 36 months at 41 sites across the United States. This study was designed and developed to confirm the benefit of using a prior course of corticosteroid as indicated in the ILUVIEN U.S. label, to mitigate the risk of uncontrolled IOP elevation. Researchers enrolled 202 eyes in 159 patients with DME who had previously received corticosteroid treatment without a clinically significant rise in IOP. All eyes were treated with ILUVIEN and patients were followed for up to 36 months. Additionally, secondary outcomes confirmed improvement in vision and reduction in treatment burden and retinal thickness variability.
About Alimera
Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 This email address is being protected from spambots. You need JavaScript enabled to view it. | For investor inquiries: Scott Gordon for Alimera This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$5.54 |
Daily Volume: | 0 |
Market Cap: | US$301.270M |
August 06, 2024 May 14, 2024 March 19, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB